Brief: Compugen Expands Clinical Collaboration Agreement With Bristol Myers Squibb With Phase 1B Combination Study Of Com701 With Opdivo®

Compugen

22/02/2021 12:33

Feb 22 (Reuters) - Compugen Ltd  CGEN.TA :
    * COMPUGEN EXPANDS CLINICAL COLLABORATION AGREEMENT WITH
BRISTOL
MYERS SQUIBB WITH PHASE 1B COMBINATION STUDY OF COM701 WITH
OPDIVO®
    * COMPUGEN LTD -  BRISTOL MYERS SQUIBB WILL SUPPLY OPDIVO
FOR
COMPUGEN'S PHASE 1B COHORT EXPANSION STUDY DESIGNED TO ASSESS
COM701
    * COMPUGEN LTD -  CO'S ANTI-PVRIG ANTIBODY, IN COMBINATION
WITH
OPDIVO IN SELECTED CANCER INDICATIONS. STUDY INITIATION IS
EXPECTED IN Q2 OF 2021

Source text for Eikon:  ID:nPn99g4mXa 
Further company coverage:  CGEN.TA 

 ((Reuters.Briefs@thomsonreuters.com;))